Tefidera sales +13% w/w, FDA probes PML case in Gilenya patient

Tecfidera (BIIB) TRx for week ending 08/23: 4,049 versus 3,593 previous.

In related news, the FDA is investigating a multifocal leukoencephalopathy case in a patient being treated with Novartis' (NVS) MS treatment Gilenya.

Although NVS says the infection is unlikely to have been caused by the drug, it's worth noting that BIIB's Tysabri increases the risk of the same infection and was briefly withdrawn from the market due to concerns.

Tecfidera is BIIB's new MS treatment and although some studies have linked an early formulation of the drug to multifocal leukoencephalopathy, a connection between Tecfidera itself and the infection is less clear.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs